RxDoctor Payments Data

Yang Yang

Clinical Cardiac Electrophysiology · Fayetteville, ARNPI 1477930295

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (44.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Biosense Webster, Inc. at 33.2% of the total.

$29,241in general payments, 2019–2025

Across 298 payments — averaging $98.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$10K
  • Biotronik Inc.$6K
  • Boston Scientific$6K
  • Abbott$3K
  • Medtronic$2K
  • Atricure, Inc.$630
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$2,2508%
  • Grants$1,3875%
  • Travel & lodging$13,10245%
  • Food & beverage$12,06741%
  • Education$4361%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,241 in reported general payments places this provider in the 60th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.

See all clinical cardiac electrophysiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$494,712
Medicare patients
1,300
Services billed
5,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$169,350
XareltoRivaroxaban38$39,580
Dofetilide45$8,870
Amiodarone Hcl166$2,366
Flecainide Acetate38$2,141
Colchicine116$1,662
Metoprolol Succinate110$1,328
SotalolSotalol Hcl30$937
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$651
Omeprazole103$510
Digoxin15$367
Potassium Chloride21$242
Carvedilol34$226
Warfarin Sodium21$199
Metoprolol Tartrate45$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$360$169,350196 claims
Johnson & JohnsonXarelto$31$39,58038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 25 clinical cardiac electrophysiology providers in Arkansas.

Other clinical cardiac electrophysiology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →